Investing in Life Sciences

Presented by

Allan Lane, Algo-Chain | Aanand Venkatramanan, LGIM

About this talk

Biotechnology has become the next revolution in the life sciences industry. It follows advances in microscopes that enable the study of bacteria and infectious diseases and chemistry that created antibiotics. More recent discoveries, such as decoding the human genome, help us anticipate illness and live longer lives. For investment managers, the life sciences, which includes Pharma and Biotechnology, is known to be an industry of consistent returns and high growth. Even before COVID-19, it was poised to reach $775 Billion by 2024. The urgency of COVID-19 and the demand for a vaccine increase the value of the industry, shown in the US government’s Operation Warp Speed, a $10 billion grant program seeking a successful vaccine. How will the value of life sciences grow as the market demands cures to existing diseases and prevention for future ailments? Join this webinar to learn about: - The true size & market outlook of the life sciences industry - How COVID-19 has affected the pace of value creation in biotechnology - What to think about when analyzing prospects for pharma and biotech companies Speakers: - Aanand Venkatramanan, ETF Investment Strategist, LGIM - Allan Lane, Co-founder, Algo-Chain

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (104)
Subscribers (4483)
View the latest videos, webcasts, news and presentations from Panacea Adviser and partners. This area provides free thought provoking webcasts to support and educate Advisers and includes general industry webcasts and those that can help advisers with their day-to-day business. The schedule of programmes is updated on a regular basis so keep coming back to stay in touch.